Medicare Enrolled
Dr. Henry Van Gieson, MD
Cardiovascular Disease · Long Beach, CA
Practice pattern: Cardiac & Electrophysiology
— Practice combining cardiac and electrophysiology services
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Van Gieson from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Van Gieson?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Van Gieson
Dr. Henry Van Gieson is a cardiovascular disease specialist in Long Beach, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Van Gieson performed 3,294 Medicare services across 2,117 unique beneficiaries.
Between the years covered by Open Payments, Dr. Van Gieson received a total of $14,949 from 55 pharmaceutical and/or device companies across 675 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in cardiovascular disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Van Gieson is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 33% volume in CA
$14,949 industry payments
Medicare Practice Summary
Medicare Utilization ↗3,294
Medicare services
Top 33% in CA for cardiovascular disease
2,117
Unique beneficiaries
$120
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~173 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
916 | $144 | $303 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
426 | $11 | $36 |
| Regadenoson injection (Lexiscan) for heart stress test An injection of regadenoson, a medication used to stress the heart during diagnostic testing. |
216 | $44 | $111 |
| EKG interpretation and report A standard electrocardiogram test that records the heart's electrical activity using at least 12 leads. The service includes a professional interpretation of the results and a written report. |
214 | $7 | $60 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
204 | $102 | $216 |
| Echocardiogram, transthoracic An ultrasound of the heart that uses color to show blood flow, rate, direction, and valve function. |
192 | $164 | $489 |
| Technetium Tc-99m sestamibi diagnostic injection A diagnostic injection of technetium Tc-99m sestamibi used for imaging studies. |
124 | $72 | $400 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
95 | $86 | $225 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
95 | $144 | $419 |
| Exercise or drug-induced heart stress test with ECG A heart stress test performed using exercise or medication while monitoring the electrocardiogram under physician supervision and review. |
94 | $63 | $163 |
| Remote pacemaker monitoring, 90 days Remote assessment of a pacemaker system, including single, dual, multiple lead, or leadless devices, performed up to 90 days apart. |
85 | $23 | $70 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
84 | $68 | $149 |
| New patient office visit, complex (60-74 min) | 80 | $172 | $429 |
| Nuclear stress test of heart muscle A nuclear medicine imaging test that evaluates blood flow to the heart muscle at rest and during stress using a special camera. |
63 | $395 | $1,057 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
53 | $180 | $569 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 53 | $416 | $2,082 |
| Sedation by physician, initial 15 minutes Administration of a drug to induce depression of consciousness by the physician performing a procedure. This code covers the initial 15 minutes of sedation for patients aged 5 years or older. |
50 | $10 | $250 |
| Intraoperative ultrasound guidance Use of ultrasound imaging during a surgical procedure to help guide the surgeon's actions. |
36 | $51 | $200 |
| Pacemaker programming, dual lead system Adjustment and configuration of a dual-lead pacemaker device to ensure proper operation and settings. |
35 | $68 | $123 |
| Radiologist review of arm or leg artery image A radiologist reviews images of the arteries in the arm or leg. This process involves analyzing the visual data to assess the blood vessels. |
34 | $69 | $200 |
| Nuclear stress test with CT scan A nuclear medicine imaging test that evaluates blood flow in the heart muscle at rest and during stress, performed alongside a concurrent CT scan. |
27 | $1,736 | $4,400 |
| PET scan of heart muscle blood flow A nuclear medicine imaging test that uses positron emission tomography (PET) to evaluate blood flow within the heart muscle. |
27 | $124 | $314 |
| Ultrasound of head and neck blood flow, bilateral An ultrasound exam that uses sound waves to visualize and assess blood flow in the vessels of both the head and the neck. |
27 | $180 | $438 |
| Cardiac catheterization | 21 | $209 | $610 |
| Continuous ECG monitoring, up to 30 days Continuous heart rhythm monitoring for up to 30 days, including professional review and reporting of the results. |
16 | $22 | $150 |
| 30-day continuous ECG with patient-triggered event transmission and review This procedure involves continuous electrocardiogram monitoring for up to 30 days, including the transmission of patient-triggered events. A healthcare professional reviews the data and provides a report. |
16 | $706 | $1,198 |
| 2-day continuous ECG with review and report A two-day continuous electrocardiogram recording that includes a professional review and written report of the results. |
11 | $63 | $196 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
10.1% high complexity
17.8% medium
72.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$14,949
Total received (2018-2024)
Avg $2,136/year across 7 years
Top 21% in CA for cardiovascular disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
55
Companies
675
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,949 (100.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,621
2023
$2,551
2022
$2,708
2021
$1,811
2020
$1,467
2019
$2,881
2018
$1,908
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Boehringer Ingelheim Pharmaceuticals, Inc.
$275
Novartis Pharmaceuticals Corporation
$211
PFIZER INC.
$183
Medtronic, Inc.
$159
AstraZeneca Pharmaceuticals LP
$157
E.R. Squibb & Sons, L.L.C.
$92
Kiniksa Pharmaceuticals International, plc
$89
Amgen Inc.
$57
SANOFI-AVENTIS U.S. LLC
$56
CARDIVA MEDICAL, INC.
$48
Janssen Pharmaceuticals, Inc
$43
SCPHARMACEUTICALS INC.
$41
Boston Scientific Corporation
$40
ANI Pharmaceuticals, Inc.
$28
Merck Sharp & Dohme LLC
$27
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$25
Abbott Laboratories
$23
Kestra Medical Technology Services, Inc.
$23
CVRx, Inc.
$23
Bayer Healthcare Pharmaceuticals Inc.
$19
Top 3 companies account for 41.2% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,619
Janssen Pharmaceuticals, Inc
$1,563
Boehringer Ingelheim Pharmaceuticals, Inc.
$1,154
PFIZER INC.
$1,136
AstraZeneca Pharmaceuticals LP
$1,087
Medtronic Vascular, Inc.
$1,033
Amgen Inc.
$903
SANOFI-AVENTIS U.S. LLC
$697
E.R. Squibb & Sons, L.L.C.
$565
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)
$488
Medtronic, Inc.
$402
Abbott Laboratories
$370
Merck Sharp & Dohme LLC
$344
Esperion Therapeutics, Inc.
$269
Gilead Sciences, Inc.
$260
Cardiovascular Systems Inc.
$198
Boston Scientific Corporation
$187
ABIOMED
$181
Actelion Pharmaceuticals US, Inc.
$180
Kiniksa Pharmaceuticals, Ltd.
$169
Bayer HealthCare Pharmaceuticals Inc.
$163
W. L. Gore & Associates, Inc.
$158
Merck Sharp & Dohme Corporation
$152
Penumbra, Inc.
$150
Regeneron Healthcare Solutions, Inc.
$148
CARDIVA MEDICAL, INC.
$137
CVRx, Inc.
$126
Kiniksa Pharmaceuticals International, plc
$89
Kestra Medical Technology Services, Inc.
$87
Amarin Pharma Inc.
$71
Allergan Inc.
$62
Kowa Pharmaceuticals America, Inc.
$60
Alnylam Pharmaceuticals Inc.
$51
Invuity, Inc.
$45
SCPHARMACEUTICALS INC.
$41
HeartFlow, Inc.
$41
BIOTRONIK INC.
$40
ARBOR PHARMACEUTICALS, INC.
$40
Astellas Pharma US Inc
$38
Bayer Healthcare Pharmaceuticals Inc.
$37
CardioFocus, Inc.
$36
Corindus Inc.
$36
Novo Nordisk Inc
$36
Philips Electronics North America Corporation
$35
Impulse Dynamics (USA) Inc.
$32
Amicus Therapeutics, Inc.
$29
Daiichi Sankyo Inc.
$28
ANI Pharmaceuticals, Inc.
$28
Chiesi USA, Inc.
$27
GENZYME CORPORATION
$23
iRhythm Technologies, Inc.
$23
Lexicon Pharmaceuticals, Inc.
$23
Biom'Up France SAS
$22
Ethicon US, LLC
$15
Aziyo Biologics, Inc.
$14
Top 3 companies account for 29.0% of all-time payments
Associated products mentioned in payments ›
(8874) inCourage · AMVUTTRA · Adempas · Arcalyst · Assure WCD · BRILINTA · BYSTOLIC · Barostim Neo System · CAMZYOS · CARDIOFORM Septal Occluder · CARDIOMEMS · CARDIVA VASCADE MVP VVCS 6-12F · CHANTIX · COBALT DR MRI SURESCAN · Cardiva VASCADE MVP VVCS 6-12F · Confirm Rx · CorPath GRX · Corlanor · Coronary Orbital Atherectomy System · ECM · ELIQUIS · ENTRESTO · Edarbi · FABRY-DISEASE · FARXIGA · FFRct · FUROSCIX · GENERAL - VASCULAR INTERVENTION · GORE CARDIOFORM Septal Occluder · HEARTLIGHT SYSTEM · HemoBlast Bellows · IGT Device Undivided · INJECTAFER · Impella · Indigo System · Inpefa · JARDIANCE · KENGREAL · Kerendia · LATITUDE · LEQVIO · LEXISCAN · Letairis · LifeVest · Livalo · MICRA · MITRACLIP · MULTAQ · MYCARELINK · NEXLETOL · NEXLIZET · OPSUMIT · OPSUMIT MACITENTAN · Optimizer · Ozempic · PRADAXA · PRALUENT · PRALUENT ALIROCUMAB INJECTION · PULSESELECT · PURIFIED CORTROPHIN GEL · Photonblade · REVEAL LINQ · Repatha · Reveal LINQ · SURGICEL Family of Absorbable Hemostats · Sentinel · UPTRAVI · VERQUVO · VYNDAQEL · Vascepa · Vascular Closure Device · VenaSeal · WATCHMAN Access System · XARELTO · ZIO Patch
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Cardiologists within 10 mi
613
Per 100K population
6.2
County median income
$87,760
Nearest hospital
MEMORIALCARE LONG BEACH MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Van Gieson is a cardiac & electrophysiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Van Gieson experienced with office visit, established patient, complex (40-54 min)?
Based on Medicare claims data, Dr. Van Gieson performed 916 office visit, established patient, complex (40-54 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Van Gieson receive payments from pharmaceutical companies?
Yes. Dr. Van Gieson received a total of $14,949 from 55 companies across 675 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Van Gieson's costs compare to other cardiologists in Long Beach?
Dr. Van Gieson's average Medicare payment per service is $120. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Van Gieson) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Cardiologists in Long Beach
Browse cardiologists in Long Beach ranked by procedure volume and transparency data.
Highest volume
Top Cardiologists in CA
Cardiologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Cardiologists in CA
Which CA cardiologists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Pharmaceuticals, Inc Payments to Doctors
See all physicians who received payments from Janssen Pharmaceuticals, Inc.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology